Pamidronate Treatment in Vertebral Fracture after Off-therapy of Medulloblastoma.
- Author:
Youn Jung LEE
1
;
Hyun Jae LEE
;
Dong Ho KIM
;
Jun A LEE
;
Kyung Duk PARK
;
Jung Sub LIM
Author Information
1. Department of Pediatrics, Korean Cancer Center Hospital. Seoul, Korea. limjs@kcch.re.kr
- Publication Type:Case Report
- Keywords:
Pamidronate;
Vertebral fracture;
Medulloblastoma;
Bone mineral density
- MeSH:
Back Pain;
Bone Density;
Fractures, Compression;
Growth Hormone;
Humans;
Hypothyroidism;
Knee Joint;
Medulloblastoma*;
Radiography
- From:Journal of Korean Society of Pediatric Endocrinology
2007;12(1):87-89
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
A twenty-one year old man, who had been treated for medulloblastoma 6 years ago, complained progressive right knee joints pain and back pain. Multiple thoracic vertebral compression fracture was detected in radiography. The bone mineral density(BMD) was in osteoporotic range in duel energy X-ray absorpometry. Growth hormone deficiency and primary hypothyroidism were detected after endocrine function test. We treated him by cyclic intravenous pamidronate because he had complained severe back pain and difficulty to walk. After pamidronate therapy, the pain was decreased and the BMD was increased. No severe adverse effect was noted. This is the first case report of pamidronate therapy in patient who had osteoporotic vertebral compression fracture due to a sequela of childhood medulloblastoma.
